Clinical Trials Browser

Phase 3 × INDUSTRY × HER2 Positive Metastatic Breast Cancer × Clear all

NCT02973737 2022-10-25

A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer

Phase 3 Unknown

HER2 Positive Metastatic Breast Cancer

NCT03080805 2020-06-18

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

Phase 3 Unknown

HER2 Positive Metastatic Breast Cancer